Optic Neuritis

Edward J. Atkins; Valérie Biousse; Nancy J. Newman

doi:10.1055/s-2007-979683

Seminars in Neurology, Table of Contents

Semin Neurol 2007; 27(3): 211-220
DOI: 10.1055/s-2007-979683

Optic Neuritis

Edward J. Atkins¹ , Valérie Biousse² ^, ³ , Nancy J. Newman² ^, ³ ^, ⁴

¹Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
²Department of Ophthalmology Surgery, Emory University School of Medicine, Atlanta, Georgia
³Department of Neurology Surgery, Emory University School of Medicine, Atlanta, Georgia
⁴Department of Neurological Surgery, Emory University School of Medicine, Atlanta, Georgia

Abstract

ABSTRACT

Optic neuritis is a common cause of visual loss in young patients. Visual function generally spontaneously improves over weeks, and 95% of patients return to visual acuity of at least 20/40 within 12 months. The initial magnetic resonance imaging (MRI) helps stratify the risk of multiple sclerosis in patients with acute isolated optic neuritis. High-dose steroids hasten the rate, but not the final extent, of visual recovery in optic neuritis, and the decision to use this therapy is individualized. Interferon therapy should be considered in selected high-risk patients.

KEYWORDS

Optic neuritis - multiple sclerosis clinically isolated syndrome - optic neuritis treatment trial

Full Text

References

REFERENCES

1 Purvin V A. Optic neuropathies for the neurologist. Semin Neurol. 2000; 20 97-110
2 Frohman E M, Frohman T C, Zee D S et al.. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005; 4 111-121
3 Miller D, Barkhof F, Montalban X, Thompson A, Filipi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005; 4 281-288
4 Miller D, Barkhof F, Montalban X, Thompson A, Filipi M. Clinically isolated syndromes suggestive of multiple sclerosis, part II: non-conventional MRI, recovery processes, and management. Lancet Neurol. 2005; 4 341-348
5 Arnold A C. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005; 139 1101-1108
6 Rizzo J F, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol. 1991; 109 1668-1672
7 Ebers G C. Optic neuritis and multiple sclerosis. Arch Neurol. 1985; 42 702-704
8 Kurtzke J F. Optic neuritis or multiple sclerosis. Arch Neurol. 1985; 42 704-710
9 Francis D A, Compston D A, Batchelor J R, McDonald W I. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry. 1987; 50 758-765
10 Miller D H, Ormerod I EC, McDonald W I et al.. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry. 1988; 51 1569-1571
11 Rizzo J F, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology. 1988; 38 185-190
12 Söderström M, Jin Y P, Hillert J, Link H. Optic neuritis, prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 1998; 50 708-714
13 Ghezzi A, Martinelli V, Torri V et al.. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999; 246 770-775
14 Brex P A, Ciccarelli O, O'Riordan J I et al.. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002; 346 158-164
15 Tintoré M, Rovira A, Rio J et al.. Is optic neuritis more benign than other first attacks in multiple sclerosis?. Ann Neurol. 2005; 57 210-215
16 Beck R W, Cleary P A, Anderson Jr M M et al.. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326 581-588
17 Optic Neuritis Study Group . Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1997; 115 1545-1552
18 Optic Neuritis Study Group . Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol. 2004; 137 77-83
19 Optic Neuritis Study Group . The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology. 1997; 49 1404-1413
20 Optic Neuritis Study Group . Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004; 61 1538-1541
21 Optic Neuritis Study Group . High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003; 121 944-949
22 Optic Neuritis Study Group . Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004; 61 1386-1389
23 Beck R W, Cleary P A, Trobe J D et al.. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993; 329 1764-1769
24 Beck R W, Arrington J, Murtagh F R et al.. Brain magnetic resonance imaging in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch Neurol. 1993; 50 841-846
25 Jacobs L D, Beck R W, Simon J H et al.. Intramuscular interferon beta-1a treatment initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000; 343 898-904
26 CHAMPS Study Group . Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001; 132 463-471
27 Beck R W, Chandler D L, Cole S R et al.. Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. 2002; 51 481-490
28 CHAMPIONS Study Group . IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006; 66 678-684
29 Comi G, Filippi M, Barkhof F et al.. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study (ETOMS). Lancet. 2001; 357 1576-1582
30 Kappos L, Polman C, Freedman M et al.. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006; 67 1242-1249
31 Brusaferri F, Candelise F. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000; 247 435-442
32 Kaufman D I, Trobe J D, Eggenberger E R et al.. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology. 2000; 54 2039-2044
33 Sellebjerg F, Nielsen H S, Frederiksen J L, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999; 52 1479-1484
34 Morrissey S P, Miller D H, Kendall B E et al.. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain. 1993; 116 135-146
35 Sandberg-Wollheim M, Bynke H, Cronqvist S et al.. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. 1990; 27 386-393
36 Jacobs L D, Kaba S E, Miller C M et al.. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol. 1997; 41 392-398
37 Nilsson P, Larsson E M, Maly-Sundgren P et al.. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005; 252 396-402
38 Jin Y P, de Pedro-Cuesta J, Huang Y H, Söderström M. Predicting multiple sclerosis at optic neuritis onset. Mult Scler. 2003; 9 135-141
39 Minneboo A, Barkhof F, Polman C H et al.. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004; 61 217-221
40 Tintoré M, Rovira A, Martinez M J et al.. Isolated demyelinating syndromes: comparison of different diagnostic MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000; 21 702-706
41 Korteweg T, Tintoré M, Uitdehaag B et al.. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 2006; 5 221-227
42 Barkhof F, Filippi M, Miller D H et al.. Isolated demyelinating syndromes: comparison of different magnetic resonance imaging criteria to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120 2059-2069
43 McDonald W I, Compston A, Edam G et al.. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50 121-127
44 Polman C H, Reingold S C, Edan G et al.. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005; 58 840-846
45 Dalton C M, Brex P A, Miszkiel K A et al.. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol. 2003; 53 673-676
46 Weinshenker B G, Bass B, Rice G P et al.. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989; 112 133-146
47 Dalton C M, Brex P A, Miszkiel K A et al.. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry. 2003; 74 1577-1580
48 Frederiksen J L. Can CSF predict the course of optic neuritis?. Mult Scler. 1998; 4 132-135
49 Rolak L A, Beck R W, Paty D W et al.. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology. 1996; 46 368-372
50 Cole S R, Beck R W, Moke P S et al.. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology. 1998; 51 885-887
51 Masjuan J, Alvarez-Cermeno J C, Garcia-Barragan N et al.. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006; 66 576-578
52 Achiron A, Kishner I, Sarova-Pinhas I et al.. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol. 2004; 61 1515-1520
53 Sorensen P S, Wanscher B, Jensen C V et al.. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998; 50 1273-1281
54 Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol. 2002; 9 565-572
55 Roed H G, Langkilde A, Sellebjerg F et al.. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005; 64 804-810
56 Revesz T. Axonal lesions in MS: an old story revisited. Brain. 2000; 123 203-204
57 De Stefano N, Narayanan S, Francis G S et al.. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001; 58 65-70
58 Filippi M, Tortorella C, Rovaris M et al.. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000; 68 157-161
59 Bermel R A, Puli S R, Rudick R A et al.. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol. 2005; 62 1371-1376
60 Frohman E M, Racke M, van Den Noort S. To treat or not to treat? The therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Arch Neurol. 2000; 57 930-932
61 Balcer L J. Clinical practice: optic neuritis. N Engl J Med. 2006; 354 1273-1280
62 Montalban X. The pros and cons of early treatment of relapsing forms of multiple sclerosis. J Neurol. 2004; 251(suppl 4) IV30-IV34
63 van Engelen B G, Hommes O R, Pinckers A et al.. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol. 1992; 32 834-835
64 Rodriguez M, Lennon V A. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol. 1990; 27 12-17
65 Rodriguez M, Miller D J. Immune promotion of central nervous system remyelination. Prog Brain Res. 1994; 103 343-355
66 van Engelen B G, Miller D J, Pavelko K D et al.. Promotion of remyelination by polyclonal immunoglobulin and IVIg in Theiler's virus-induced demyelination and in MS. J Neurol Neurosurg Psychiatry. 1994; 57(suppl 1) 65-68
67 Rodriguez M, Miller D J, Lennon V A. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology. 1996; 46 538-545
68 Noseworthy J H, O'Brien P C, Petterson T M et al.. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001; 56 1514-1522
69 Boomer J A, Siatkowski R M. Optic neuritis in adults and children. Semin Ophthalmol. 2003; 18 174-180
70 Brady K M, Brar A S, Lee A G et al.. Optic neuritis in children: clinical features and visual outcome. J AAPOS. 1999; 3 98-103
71 Morales D S, Siatkowski R M, Howard C W, Warman R. Optic neuritis in children. J Pediatr Ophthalmol Strabismus. 2000; 37 254-259
72 Lucchinetti C F, Kiers L, O'Duffy A et al.. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology. 1997; 49 1413-1418

Valérie BiousseM.D.

Neuro-Ophthalmology Unit, Emory Eye Center

1365-B Clifton Road NE, Atlanta, GA 30322